Purchase Order 75F40120P00058
Award Date 1/17/20
Potential Completion Date 2/10/25
Potential Value $170K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Laurel, MD, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services Food and Drug Administration awarded a $534,031 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System to be delivered to Silver Spring, Maryland. The solicitation notice indicated the FDA requires this sequencing system to adapt standard operating procedures for its currently installed Illumina NextSeq 500 model, scale up sequencing...
- The Department of Health and Human Services Food and Drug Administration awarded a $457,531.00 firm fixed price purchase order to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract is for the delivery of an ILLUMINA NEXTSEQ 2000 SEQUENCING SYSTEM, plus a preventative maintenance agreement, to be performed in Silver Spring, Maryland. This award does not have a set-aside designation. Illumina has a history of providing sequencing systems and related...
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
- The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $341,700 purchase order to Illumina, Inc. to provide one (1) Illumina NextSeq 2000 System. The place of performance for this firm fixed price contract is Silver Spring, Maryland. The period of performance is from September 29, 2022 through October 29, 2023. The NextSeq 2000 System is a benchtop high-throughput sequencing platform that enables DNA and RNA sequencing applications. No applicable...
- The U.S. Food and Drug Administration (FDA) awarded Illumina, Inc. a firm fixed-price purchase order contract worth $233,747.00 to provide an Illumina NextSeq 2000 Sequencing System and one year of post-warranty maintenance. The contract has an ultimate completion date of October 14, 2026. This award is not associated with a larger contract vehicle and does not have a set-aside designation. Illumina, Inc. is a for-profit manufacturer of sequencing and genomic analysis instruments and reagents....
- The Department of Health and Human Services Food and Drug Administration awarded a $19,283.10 firm fixed price purchase order to Illumina, Inc. to provide Illumina ISEQ 100 Systems. The ISEQ 100 Systems will be used for quality control and rebalancing of samples in sample pools. The systems are compatible with Illumina's library preparation kits and provide fast, cost-effective small-scale runs. The place of performance is Illumina's facilities in San Diego, California, and the period of...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for NEXTSEQ 500 comprehensive plan service maintenance for two NextSeq 500 sequencing systems at the FDA's location in Berwyn Heights, Maryland. The contract has a ceiling value of $265,801.32 and a period of performance through September 30, 2021. This contract does not have a...
- The U.S. Food and Drug Administration awarded a $219,300 firm fixed price purchase order to Illumina, Inc. for a NextSeq 2000 Sequencing System. This award was not subject to any set-aside provisions. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has been awarded past federal contracts with agencies such as the NIH, CDC, USDA, and VA to provide a range of sequencing systems and related products. The award references an original small business...
- This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the provision of a NextSeq 500 Sequencing System, with a ceiling value of $292,000.00 and a completion date of September 23, 2016. The contract does not have a set-aside designation. Illumina has previously been awarded prime federal contracts and subcontracts by various...
- This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a biotechnology company specializing in genetic sequencing and genomic analysis technologies. The contract is for the procurement of an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System, including installation, training, warranty, and preventative maintenance. The original solicitation was a Request for Quotation (RFQ) with a potential incumbent of Illumina, Inc....